Biointron’s Q1 2026 Antibody Industry Trends report aims to explore the events and trends of the biopharmaceutical industry in January, February, and March. This quarter, three novel monoclonal antibody drugs have been approved by China.
Bispecific antibody-drug conjugates, or BsADCs, combines the payload-delivery function of an ADC with the dual-recognition capacity of a bispecific antibody. Instead of binding one antigen or one epitope, the antibody component can be designed to recognize two different antigens, or two distinct epitopes on the same antigen. This added specificity may improve tumor selectivity, increase internalization, or broaden activity across heterogeneous tumors.
Programmable antibodies can describe several related approaches that make antibody-based systems more designable and controllable. A traditional antibody has two main functional parts: the Fab region, which recognizes a target antigen, and the Fc region, which interacts with immune receptors and helps determine downstream immune activity.
Time: April 15 - 19, 2026
Location: Boston, MA
Booth: #1228
Time: April 28 – 30, 2026
Location: Seoul, South Korea
Booth: #B31
Time: May 9 - 10, 2026
Location: Boston, MA
Biointron’s 2026 Lunch & Learn, held at CIC Cambridge on May 8, 2026, featured expert presentations from SeromYx Systems and Visterra on two critical areas of antibody and biologic development: Fc-effector function profiling and cell-based neutralizing antibody (NAB) assay design.
This webinar provides an overview of Antibody-Drug Conjugates (ADCs) and expanded drug conjugates (XDCs), with a focus on Biointron's experiences and capabilities.
Watch our webinar on accelerating antibody discoveru. Single B cell sorting-based antibody screening can help identify a population of diverse and functional hits with a shortened timeline. Integrated with our high-throughput expression, validation and developability assay platforms, the path from hits to candidate can be more faster and more efficient with data beyond binding alone.
When you’re a small biotech with big ambitions, every week counts. For Macomics Limited, that meant finding a way to get high-quality antibodies quick···
The demand for fully human therapeutic antibodies continues to grow, driving the need for more efficient discovery platforms.
Case 1: Tag-Free Vaccine Protein. During the generation of stable cell lines, cells are selected and screened to identify clones that stably express t···
Apply for Biointron's Quarterly Travel Grant. Receive $800 to support early-career antibody researchers in attending scientific conferences, symposia, and workshops.
Submit a quick Biointron testimonial and we’ll send you a $25 Amazon gift card. Simple, fast, and appreciated!
Get 25% off your next Biointron project when you cite us in your paper!
Spotlight on Antibodies is a podcast from Biointron, where we bring you the latest antibody industry trends. This month in May, we'll highlight the future of VHH technology, chemical conjugation in antibody therapeutics, and emerging trends in antibody characterization.
Spotlight on Antibodies is a podcast from Biointron, where we bring you the latest antibody industry trends. This month in April, we'll highlight ATP-dependent switch antibodies, the throughput-quality gap in antibody discovery, and multiple myeloma antibody treatments.
Spotlight on Antibodies is a podcast from Biointron, where we bring you the latest antibody industry trends. This month in March, we'll highlight antibody allostery, trends in developability, and anti-IgE therapeutics.
In this article, we explore the major trends shaping the future of targeted cancer drug delivery, and why integrated expertise in antibody discovery, engineering, and conjugation is becoming increasingly important for successful ADC development.
Site-specific conjugation limits payload attachment to defined positions on the antibody instead of allowing reaction across many accessible residues. As ADC design becomes more sophisticated, this level of control is increasingly important.
Affinity maturation can improve binding to the intended target, but it can also alter the antibody paratope (the antigen-binding surface) in ways that create patch-associated nonspecific interactions. These liabilities may then require re-engineering before a candidate can progress as a therapeutic lead.
You can also contact us on the Scientist and Science Exchange marketplaces.
